Switching From HIV Protease Inhibitors to Integrase Strand Transfer Inhibitors Tied to Diabetes Risk
Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a stu ...
Using rapid protein degradation, chemogenomics, and super‑resolution microscopy in mouse embryonic stem cells, the team dissected the distinct contributions of BRD2 and BRD4 to transcription.
For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The ...
Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to ...
Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to ...
In a new Johns Hopkins Medicine study funded by the National Institutes of Health, researchers found adults with HIV who switched from protease inhibitors to integrase inhibitors were at increased ...
The table below is a review of notable updates that occurred in February 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
A new once-daily HIV pill combining doravirine and islatravir shows strong safety and effectiveness, offering a promising alternative to existing therapies Researchers at Queen Mary University of ...
The table below is a review of notable updates that occurred in November 2025 for investigational products in development (not an inclusive list). Click on the status ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results